Stay up to date on the latest oncology and nursing conferences.
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus panitumumab in CRC.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care
Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.
AI Tool May Predict Response, Resistance in Advanced RCC
A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.
Olanzapine May Reduce Nausea, Vomiting From Radiation
Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.
Pembrolizumab Plus CCRT Could Become SOC in High-Risk Cervical Cancer
Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.
Zilovertamab Vedotin Plus R-GemOx Shows Activity in R/R DLBCL
The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.
Luspatercept Improves Transfusion Independence in Lower-Risk MDS
Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.
Nurses, APPs Can Help Prevent Parkinsonism During Cilta-Cel in Myeloma
By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.
Chemo With Molecular Guidance Improves Survival in Early NSCLC
A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.
Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC
Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.
First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC
The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.
Dermatologic Protocol Preserves QOL in EGFR+ Advanced NSCLC Treatment
COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.
Peripheral Neuropathy Treatable With Teliso-V in C–Met-High NSCLC
Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.
PROs Higher For Imlunestrant With/Without Abemaciclib in ER+, HER2– BC
Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.
Niraparib Plus Abiraterone Improves rPFS in HRR-Mutated mCSPC
The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.
T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors
Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.
Physical Activity Ups DFS, OS After Surgery/Chemo in Colorectal Cancer
Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free and overall survival.
Durvalumab/FLOT Potential SOC in Resectable Gastric/GEJ Adenocarcinoma
Adding durvalumab to perioperative FLOT upped event-free survival in patients with gastric or gastroesophageal adenocarcinoma eligible for resection.
Camizestrant/CDK4/6 Inhibition Boosts PFS in ESR1+ Advanced Breast Cancer
Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.
Adding Nivolumab to Chemo/RT Yields Higher DFS in Head/Neck Cancer
NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with cisplatin/radiotherapy in LA-SCCHN.
Atezolizumab Plus Chemo Boosts DFS in Stage III dMMR Colon Cancer
Atezolizumab plus chemotherapy reduced risk of death or recurrence by 50% compared with chemotherapy alone for patients with stage III dMMR colon cancer.
Anti-Inflammatory Diet/Exercise Promotes OS in Advanced Colon Cancer
Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical activity.
Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC
Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
T-DXd Earns Second-Line SOC for HER2+ Gastric/GEJ Cancer
T-DXd led to improvements in OS, PFS, ORR, and DOR compared with ramucirumab/paclitaxel in the second line for HER2-positive gastric and GEJ cancer.
Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer
Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.
